Heart failure & cardiomyopathiesSecondary analysis
Changes in Natriuretic Peptide Levels Following Patiromer-Enabled Optimization of Medical Therapy In Heart Failure: A Post Hoc Analysis of the DIAMOND Study
- Post hoc analysis of the DIAMOND randomised trial
- single-blinded patiromer run-in
- randomized withdrawal phase
Authors' conclusion
In this post-hoc analysis of DIAMOND, patients with HFrEF and elevated (>1000 ng/ml) NT-proBNP at screening experienced clinically meaningful NT-proBNP reductions following a RAASi optimization strategy that included patiromer during the run-in phase, with no significant differences observed between patiromer and placebo groups during the randomized withdrawal phase.
Study context
- Population
- Heart failure and a reduced ejection fraction (HFrEF) with current or recent hyperkalaemia and screening NT-proBNP ≥1000 pg/ml337 with follow-up NT-proBNP
- Participants
- 539 participants
- Comparison
- Patiromer vs placebo after patiromer-enabled renin-angiotensin-aldosterone system inhibitors (RAASi) optimisation
- Patiromern = 266
- Placebon = 273reference
- Primary endpoint
- Change in NT-proBNP from screening
- Follow-up
- Week 18 after randomization
Primary result
As reported in the abstract
NT-proBNP decline, both arms combined
−53% (95% CI −59% to −46%; p < 0.001)
Median absolute change, both arms combined
−731 [−1832, 107] pg/ml
Further findings
>30% NT-proBNP reduction · week 18
P = 0.38
NT-proBNP <1000 pg/ml · week 18
P = 0.30
- >30% NT-proBNP reduction: denominators 165 and 172
Original publication
Summarised from the published abstract; every number is checked against it